logo

Eiger Biopharmaceuticals Inc. (EIGR)



Trade EIGR now with
  Date
  Headline
11/9/2018 8:07:01 AM Eiger BioPharmaceuticals Q3 Net Loss $17.1 Mln Or $1.20/Shr Vs Net Loss $9.2 Mln Or $1.10/Shr Last Year
10/23/2018 9:16:28 AM Eiger Prices Public Offering Of 4.2 Mln Shares At $10.35/Shr
10/22/2018 4:12:39 PM Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
10/22/2018 8:14:23 AM Eiger BioPharma Gets FDA Rare Pediatric Disease Designation For Lonafarnib
9/24/2018 8:10:18 AM Eiger Announces FDA Guidance On HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
8/13/2018 8:07:13 AM Eiger BioPharma Announces Completion Of Enrollment In Phase 2 PREVENT Study Of Avexitide
8/13/2018 7:27:30 AM Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) FY19 Estimate To -2.60 From -2.78
8/13/2018 7:27:13 AM Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) Q4 19 Estimate To -0.69 From -0.73
8/13/2018 7:26:51 AM Wedbush Is Raising Eiger BioPharmaceuticals Inc. (EIGR) Q3 19 Estimate To -0.66 From -0.71
8/13/2018 7:26:33 AM Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) Q2 19 Estimate To -0.64 From -0.68
8/13/2018 7:26:22 AM Wedbush Is Raising Eiger BioPharmaceuticals Inc. (EIGR) Q1 19 Estimate To -0.61 From -0.66
8/13/2018 7:26:09 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) FY18 Estimate To -2.71 From -2.65
8/13/2018 7:25:46 AM Wedbush Reiterates Eiger BioPharmaceuticals Inc. (EIGR) At Outperform With $53 Price Target
8/10/2018 8:05:06 AM Eiger BioPharma Q2 Net Loss $9.9 Mln Or $0.82/shr Vs. Net Loss Of $11.1 Mln Or $1.33/shr Prior Year
6/4/2018 8:16:53 AM Eiger BioPharma Announces HDV Phase 2 Program Oral Presentation For Planned HDV Phase 3 D-LIVR Study
5/17/2018 7:21:11 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) FY19 Estimate To -2.78 From -2.42
5/17/2018 7:20:59 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q4 19 Estimate To -0.73 From -0.64